

1 **Comparison of dried blood spots and venous blood for the detection of SARS-CoV-2**  
2 **antibodies in a population of nursing home residents.**

3 Eline Meyers<sup>1\*</sup>, Stefan Heytens<sup>2\*</sup>, Asangwing Formukong<sup>1</sup>, Hanne Verduyck<sup>3</sup>, An De Sutter<sup>2</sup>,  
4 Tom Geens<sup>3</sup>, Kenneth Hofkens<sup>1</sup>, Heidi Janssens<sup>3</sup>, Eveline Nys<sup>4</sup>, Elizaveta Padalko<sup>1,4</sup>, Ellen  
5 Deschepper<sup>5</sup>, Piet Cools<sup>1#</sup>

6  
7 <sup>1</sup> Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent  
8 University, Ghent, Belgium

9 <sup>2</sup> Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences,  
10 Ghent University, Ghent, Belgium

11 <sup>3</sup> Research and analytics, Liantis Occupational Health Services, Bruges, Belgium

12 <sup>4</sup> Laboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium

13 <sup>5</sup> Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

14

15

16 Running Title: Dried blood spots for SARS-CoV-2 serology.

17

18 \*Both authors contributed equally to this work. Author order was determined in order of  
19 increasing seniority.

20 #Corresponding author: Prof. Dr. Piet Cools, [piet.cools@ugent.be](mailto:piet.cools@ugent.be)

21

22

23

24

25 **Abstract**

26 **Introduction**

27 In the current SARS-CoV-2 pandemic, testing for SARS-CoV-2 specific antibodies is  
28 paramount to monitor immune responses in post-authorization vaccination and sero-  
29 epidemiology studies. However, large scale and iterative serological testing by venipuncture  
30 in older persons can be challenging. Capillary blood sampled using a finger prick and collected  
31 on protein saver cards, i.e., dried blood spots (DBS), has already proven to be a promising  
32 alternative. However, elderly persons have a reduced cutaneous microvasculature, which may  
33 affect DBS-based antibody testing. Therefore, we aimed to evaluate the performance of DBS  
34 for the detection of SARS-CoV-2 antibodies in nursing homes residents.

35 **Materials and methods**

36 We collected venous blood and paired Whatman and EUROIMMUN DBS from nursing home  
37 residents, and from staff as a reference population. Venous blood samples were analyzed for  
38 the presence of SARS-CoV-2 IgG antibodies using the Abbot chemiluminescent microparticle  
39 immunoassay (CMIA). DBS were analyzed by the EUROIMMUN enzyme-linked immuno  
40 sorbent assay (ELISA) for SARS-CoV-2 IgG antibodies. We performed a statistical  
41 assessment to optimize the ELISA cut-off value for the DBS using the Youden's J index.

42 **Results**

43 A total of 273 paired DBS-serum samples were analyzed, of which 129 were positive as  
44 assessed by the reference test. The sensitivities and specificities of DBS ranged from 95.0%  
45 to 97.1% and from 97.1% to 98.8%, respectively, depending on population (residents or staff)  
46 or DBS card type.

47 **Conclusion**

48 DBS sampling is a valid alternative to venipuncture for the detection of SARS-CoV-2 antibodies  
49 in the elderly.

50

51

52

53 **Keywords**

54 Elderly, nursing homes, SARS-CoV-2, COVID-19, antibodies, immunoglobins, IgG, serology,  
55 dried blood spots (DBS), enzyme-linked immunosorbent assay (ELISA), serosurveillance,  
56 vaccination

57

58 **Introduction**

59 In the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic,  
60 large-scale serological antibody studies are paramount to assess the true SARS-CoV-2  
61 infection rate.

62 Indeed, statistics on PCR-confirmed SARS-CoV-2 cases are far from ideal to estimate the true  
63 proportion of the population that experienced a SARS-CoV-2 infection (1), as mildly affected  
64 or asymptomatic individuals are often not tested and PCR-based testing only yields an  
65 epidemiological snapshot. Furthermore, the recent implementation of newly developed SARS-  
66 CoV-2 vaccines creates an urgent need for population-based serological studies to monitor  
67 antibody responses post-authorization. Protocols for SARS-CoV-2 antibody assays using  
68 serum/plasma obtained by venipuncture are well established in a clinical setting. However,  
69 venipuncture is invasive and can cause serious discomfort. Especially in the elderly,  
70 venipuncture poses large challenges due to dehydration, loss of vein patency and low blood  
71 pressure. Elderly may also suffer from arthritis, injury or stroke, impeding to hyperextend the  
72 arms to survey for available veins. The use of venipuncture is further limited for wider  
73 application in non-clinical settings due to the costs (for e.g., phlebotomists), logistical  
74 constraints associated with collecting, processing, and transporting venous blood.

75 Collecting capillary blood on protein saver cards after finger pricking using a lancet, the so-  
76 called dried blood spot (DBS), is a most valuable alternative as it is minimally invasive, can be  
77 done at low cost, has the potential for self-sampling and is easy to ship and store. DBS are  
78 increasingly applied as a minimally invasive alternative for infectious serology, especially in  
79 community- and population-based epidemiology, including SARS-CoV-2 (2). However, the use  
80 of DBS has not yet been validated for detection of SARS-CoV-2 antibodies in the elderly. Aging

81 is known to modify the cutaneous microvasculature and the structures of blood vessels, even  
82 down to the level of the capillary basement membrane (3). Here, we aimed to validate the use  
83 of DBS sampling for the detection of SARS-CoV-2 IgG antibodies in a population of residents  
84 and staff from nursing homes.

85

## 86 **Methodology**

### 87 *Ethical considerations*

88 The current study was approved by the Ethical Committee of the Ghent University Hospital  
89 (reference number BC-07665) and conducted according to the principles outlined in the  
90 Declaration of Helsinki. Each participant signed an informed consent form after being informed  
91 about the goal of the study and the sampling procedures. A confidential counselor, such as a  
92 nurse, signed for participants who were incapable to sign the consent form, such as residents  
93 with dementia when consent was given by their legal representative.

94

### 95 *Study population*

96 In August 2020, we contacted the management of four NHs within our network (Amphora,  
97 Wingene; Sint-Rafaël, Liedekerke; Sint-Jozef, Assenede and Sint-Jozef, Wetteren; all in  
98 Flanders, Belgium) and explained the goal of the study. We recruited NHs that experienced a  
99 SARS-CoV-2 outbreak in the period March to July 2020 in order to increase the likelihood of  
100 obtaining seropositive samples, hence minimizing the number of screened participants needed  
101 to obtain our sample size. The management informed the families of residents and recruited a  
102 total of 199 residents and 241 staff members interested in participating in our study.

103

### 104 *Sample collection*

105 We obtained approximately 5 ml of venous blood from each participant by venipuncture in  
106 serum tubes using a 23G scalp vein set. Capillary blood was collected after briefly puncturing  
107 the top edge of the distal phalanx of the middle or ring finger using 18G safety lancets  
108 (Sarstedt, Numbrecht, Germany) onto Whatman protein saver cards (Whatman™, GE

109 Healthcare Sciences, Cardiff, UK). During sample collections, the protein saver card of  
110 EUROIMMUN (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) was  
111 marketed and also evaluated on a subset of participants together with the Whatman protein  
112 saver cards. For each protein saver card, a preprinted circle was filled until saturated (i.e.,  
113 blood was visible on the backside of the card). In order to avoid sampling bias, for half of the  
114 participants (i.e., those with an even participant identification number), first a circle was filled  
115 on the Whatman protein saver card, and then on the EUROIMMUN protein saver card, while  
116 for the other half of the participants (those with an odd number), the opposite was done.  
117 Typically, an average of four blood drops were needed to saturate one circle. All blood  
118 collections were done under aseptic conditions. DBS were obtained by allowing the capillary  
119 blood to air-dry on the protein saver cards for one hour at room temperature.

120 Serum tubes were transported to the Laboratory of Clinical Microbiology of the Ghent  
121 University Hospital (Ghent, Belgium) within six hours after sample collection. Upon arrival,  
122 serum tubes were centrifuged at 3000 g for 8 minutes, and tubes were stored at 4 °C. The  
123 following day, serum was aliquoted into new serum vials and analyzed by means of Abbott  
124 SARS-CoV-2 IgG Architect immunoassay (Abbott Laboratories). DBS selected for analysis  
125 (see further) were analyzed maximum two days after collection.

126

127 *SARS-CoV-2 IgG detection in sera by means of chemiluminescent microparticle immunoassay*  
128 *(CMIA)*

129 All serum samples were analyzed for anti-nucleocapsid SARS-CoV-2 IgG serology by using  
130 the Architect i2000sr Plus system (Abbott). This system allows high-throughput screening of  
131 the sera, providing real-time information on the number of positive samples. This way, we could  
132 rapidly validate DBS for our ongoing and future studies in NHs. The Architect i2000sr Plus  
133 system uses the chemiluminescent microparticle immunoassay (CMIA)-technique to detect  
134 antibodies. After thawing the sera and vortexing briefly, the Architect system analyzes the  
135 samples automatically using a SARS-CoV-2 assay, a specific calibrator kit and a specific

136 control kit. We used an in-house validated cut-off index of 0.9 to classify sera as positive ( $\geq 0.9$ )  
137 or negative ( $< 0.9$ ) for SARS-CoV-2 IgG antibodies.

138

### 139 *SARS-CoV-2 IgG detection in dried blood spots by means of ELISA*

140 The DBS were analyzed for the presence of anti-spike (S1-antigen) SARS-CoV-2 IgG  
141 antibodies by means of ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck,  
142 Germany), and not the Abbot CMIA, because this assay requires a volume of 150  $\mu\text{l}$ , which is  
143 more than the volume of capillary blood absorbed on one circle of the DBS. From each DBS  
144 card, one circle of 6 mm diameter was cut out using a puncher and placed into the well of a  
145 sterile 96-well U-shaped microtiter plate. To avoid cross-contamination, the puncher was  
146 cleaned using a 70% alcohol solution and cotton swab in between punching. A total volume of  
147 250  $\mu\text{l}$  preheated (1 hour at 37°C) sample buffer was added to each sample well of the 96-well  
148 microtiter plate and incubated at 37 °C for 1 h. After gently mixing the eluate by means of up-  
149 and-down pipetting, a total of 100  $\mu\text{l}$  of this eluate was used for ELISA, according to the  
150 manufacturer's instructions. The ELISA was run on the automated Behring Elisa Processor III  
151 (SIEMENS AG, Munich, Germany). DBS were classified according to their antibody index  
152 optical density (OD) value as negative ( $< 1.1$ ) or positive ( $\geq 1.1$ ), as recommended by the  
153 manufacturer. The borderline category was not considered.

154


### 155 *Sample size and analysis*

156 The sample size was calculated using the methodology described by Buderer (1996), focusing  
157 on the sensitivity (4). Here, we hypothesized sensitivity of DBS to be lower compared to sera  
158 due to antibodies being affected by or remaining captured in the protein saver cards. Using an  
159 anticipated sensitivity of 85%, an  $\alpha$  level of 0.05 and a precision parameter ( $\epsilon$ ) of 0.10, we  
160 needed a minimum of 49 positive sera, which were collected for both the residents and staff.  
161 The sensitivity and specificity of the DBS were calculated using the Abbott CMIA on sera from  
162 venous blood as a reference test. The 95% confidence intervals (CI) were calculated using the  
163 Wilson-Brown method (5).

164 To determine the optimal cut-off value for the Whatman and EUROIMMUN DBS test, we  
165 calculated Youden's J-index statistic, and the accuracy was calculated using the area under  
166 the curve (AUC) of the receiver operating characteristic (ROC) curves.  
167 All analyses were performed using the statistical software GraphPad Prism 6 (GraphPad  
168 Software Inc., San Diego, U.S.).

## 169 Results

170 In four NHs, a total of 440 paired venous blood - Whatman DBS samples were obtained, of  
171 which 199 were from residents and 241 from staff (Figure 1). The sera from these 440 venous  
172 blood samples were screened by means of the Abbott IgG CMIA reference assay. Of these  
173 samples, 129 samples were found positive (60 residents and 69 staff). The paired Whatman  
174 DBS from these positive sera, together with 144 paired Whatman DBS samples from negative  
175 sera, were analyzed by means of ELISA. The selection of paired DBS from negative sera  
176 included 85 paired samples from residents and 59 from staff. The mean age of residents and  
177 staff of which the paired sera-Whatman DBS were analyzed was 87.8 years (range 67-100)  
178 and 42.8 years (range 19-65), respectively. A total of 80.0% and 93.8% of residents and staff,  
179 respectively, were female. Additionally, a subset of 150 EUROIMMUNE DBS samples were  
180 analyzed, of which 82 were found positive (32 residents and 50 staff) by the reference test  
181 (Figure 1).



193 **Figure 1. Schematic figure of the collection, screening and analysis of sera and dried**  
194 **blood spots.** CMIA, chemiluminescent microparticle immunoassay; DBS, dried blood spot; EI,  
195 EUROIMMUN; ELISA, enzyme-linked immunosorbent assay; WM, Whatman.

196



197 The crosstabs with the number of true/false positives and negatives of the Whatman DBS and  
198 EUROIMMUN DBS in comparison with the reference test for all participants and categorized  
199 per residents and staff, is shown in Table 1. One of the two false-positive Whatman DBS test  
200 results with an optical density (OD) value of 4.39, was obtained from a participant who tested  
201 positive (RT-PCR) for SARS-CoV-2 in March 2020, making it unlikely that this DBS  
202 seropositivity was false-positive, in contrast, the reference test likely was falsely negative. The  
203 sensitivity and specificity of both the Whatman DBS and the EUROIMMUN DBS compared to  
204 the Abbott CMIA as a reference test is shown in Table 2.

205

206 **Table 1. The number SARS-CoV-2 IgG true/false positive and true/false negative**  
207 **Whatman (WM) DBS and EUROIMMUN (EI) DBS in comparison to the Abbott CMIA**  
208 **reference test.**

		Reference test (CMIA on venous blood)	
		positive	negative
<b>DBS WM total</b>	positive	124	2
	negative	5	142
<b>DBS WM</b>	positive	57	1
	negative	3	84
<b>DBS WM staff</b>	positive	67	1
	negative	2	58
<b>DBS EI total</b>	positive	78	2
	negative	4	66
<b>DBS EI</b>	positive	31	1
	negative	1	33
<b>DBS EI staff</b>	positive	47	1
	negative	3	33

209

210

211

212


213

214 **Table 2. Sensitivity and specificity of the Whatman (WM) and EUROIMMUN (EI) dried**  
215 **blood spot ELISA in comparison with the Abbott CMIA as the reference test<sup>a</sup>.**

	<b>SEN (%)</b>	<b>95% CI</b>	<b>SPE (%)</b>	<b>95% CI</b>
<b>DBS WM total</b>	96.1	91.2-98.7	98.6	95.1-99.8
<b>DBS WM</b>	95.0	86.3-98.6	98.8	93.6-99.9
<b>DBS WM staff</b>	97.1	90.0-99.5	98.3	91.0-99.1
<b>DBS EI total</b>	95.1	88.1-98.1	97.1	89.9-99.5
<b>DBS EI residents</b>	96.7	84.3-99.8	97.1	85.1-99.9
<b>DBS EI staff</b>	94.0	83.8-98.4	97.1	85.1-99.9

216 <sup>a</sup>CMIA, chemiluminescent microparticle immunoassay; CI, confidence interval; DBS, dried  
217 blood spot; EI, EUROIMMUN; SEN, sensitivity; SPE, specificity; WM, Whatman.

218  
219 The scatter plot of the index values of the reference test (Abbot CMIA) and the OD values of  
220 the ELISA Whatman DBS is shown in Figure 2. The Pearson correlation coefficient for the  
221 reference test and the Whatman DBS was 0.80 (95% CI, 0.75 to 0.84) and significant  
222 ( $p < 0.0001$ ). The Pearson correlation coefficient for the reference test and the EUROIMMUN  
223 DBS was 0.78 (95% CI, 0.73 to 0.82) and significant ( $p < 0.0001$ ) (scatterplot similar to  
224 reference test versus Whatman DBS, data not shown). A scatter plot showing the correlation  
225 between the optical density (OD) values from the 150 paired Whatman and EUROIMMUN DBS  
226 is depicted in Figure 2. The Pearson correlation coefficient was found to be 0.970 (95% CI,  
227 0.959 - 0.978) and significant ( $p < 0.0001$ ). Of one paired sample, the Whatman DBS showed  
228 a positive result (OD 1.41), but not the EUROIMMUN DBS (OD 1.02). However, the latter is  
229 classified as borderline when following the manufacturer's guidelines. This category was not  
230 considered in the current analysis and classified as negative.




231

232 **Figure 2. Scatter plot of paired sera and Whatman DBS (left) and Whatman DBS and**  
233 **EUROIMMUN DBS (right) optical density/index values.** Axes represent the log<sub>10</sub> of the  
234 optical density and index values. DBS, dried blood spot; FN, false negatives; FP, false  
235 positives; OD, optical density. The grey horizontal and vertical lines represent cutoff lines  
236 defining positive samples.

237 To verify if the ELISA Whatman and EUROIMMUN DBS cutoff could be optimized, we  
238 performed a ROC analysis. The ROC curves are shown in Figure 3. The area under the curve  
239 was 0.999 for both Whatman and EUROIMMUN DBS (95% CI, 0.999 to 1.000) ( $p < 0.0001$ ).  
240 The optimal cut-off point for Whatman DBS was found to be 1.14, which is almost exactly the  
241 value of 1.1 proposed by the manufacturer of the ELISA assay, and did not improve sensitivity  
242 or specificity. The optimal cut-off point for EUROIMMUN DBS was found to be 1.02 and  
243 applying this cutoff improved both sensitivity (from 95.1% to 96.4%) and specificity (from 97.1%  
244 to 98.5%).

245



246

247 **Figure 3. Receiver operating characteristics (ROC) curve for the evaluation of the**

248 **Whatman DBS ELISA (left) and EUROIMMUN (right) compared to the reference assay.**

249 The area under the curve is 0.999 for both Whatman and EUROIMMUN DBS (95% CI, 0.999

250 to 1.000) ( $p < 0.0001$ ).

251

## 252 **Discussion**

253 In the present study, we evaluated the use of DBS for detection of SARS-CoV-2 antibodies in  
254 residents and staff from nursing homes. To the best of our knowledge, we report the largest  
255 clinical DBS validation study, comparing two different DBS samples (Whatman and  
256 EUROIMMUN) in a key target population in the current SARS-CoV-2 pandemic, the elderly  
257 persons residing in NH.

258 Overall, we demonstrated a high sensitivity (range 95.0-97.1%) and specificity (range 97.1-  
259 98.8%) for DBS compared to sera. Adjustment of the manufacturer recommended cut-off from  
260 1.1 to 1.02 resulted in a slight improvement of sensitivity and specificity for EUROIMMUN DBS  
261 only. We found no significant differences in sensitivity or specificity of the DBS between  
262 residents and staff, for both Whatman and EUROIMMUN DBS, as demonstrated by the largely  
263 overlapping confidence intervals. Furthermore, protein saver cards of Whatman and  
264 EUROIMMUN yielded results that were nearly in perfect agreement.

265 Several other studies in different populations, such as health care workers, key workers,  
266 athletes and children have evaluated DBS sampling for SAR-CoV-2 antibody testing (6-14). In  
267 these studies, similar test characteristics were reported with a sensitivity ranging from 89 up  
268 to 100% and a specificity of 100% (7, 10, 11), or, reported a nearly perfect agreement in SARS-  
269 CoV-2 antibody detection between DBS samples and paired venous blood samples (6, 9, 12-  
270 14). However, some studies were limited by the lack of serum serology as a reference test (7,  
271 8) or the rather limited sample size (i.e., <50 positives as assessed by the reference test) (6,  
272 7, 11, 12).

273 Our findings show an excellent diagnostic performance of DBS, both in the elderly and staff  
274 from nursing homes. This supports the use of DBS in large-scale SARS-CoV-2  
275 serosurveillance studies as a valuable alternative to venipuncture, especially in the elderly,  
276 where venous blood can be challenging to obtain. In comparison to serological rapid tests,  
277 which can also be implemented in large-scale SARS-CoV-2 sero-epidemiological studies, DBS  
278 offer higher sensitivity, specificity and the possibility to (semi-)quantitatively assess the antibody  
279 response (15). Moreover, DBS have the advantage to collect and store the sample for multiple

280 analyses. In this way, different assays can be used on the same sample, such as antibody  
281 assay directed against different antigens. Yet, DBS have similar advantages as these rapid  
282 tests, as they alleviate the need for health care professionals during sampling and complex  
283 shipment and storage.

284 Especially since the implementation of newly developed SARS-CoV-2 vaccines, serology  
285 studies are of increasing importance to fill existing research gaps. Until now, the stability and  
286 duration of the antibody response upon vaccination is unknown, however, is important to  
287 determine if annual boosting is needed. Secondly, a correct antibody response cut-off value  
288 that refers to clinical immunity against SARS-CoV-2 is lacking. Additionally, it is of crucial  
289 importance to assess the effectiveness of the vaccines among the general population, which  
290 can differentiate from what is measured in standardized clinical trials. In this context, the non-  
291 invasiveness of the DBS, minimal logistic constraints, excellent test characteristics and the  
292 possibility for quantitative assessment bring added value in the conduct of serosurveillance  
293 studies.

294 Our study was limited by the use of CMIA on venous blood samples that assessed  
295 nucleocapsid antibodies, and not spike antibodies, which were detected by means of ELISA  
296 in DBS. Conflicting results are available concerning the degree of persistence between  
297 antibodies directed against the nucleocapsid and spike antigen, however, it is suggested that  
298 IgG antibody levels directed against the nucleocapsid antigen wane more rapidly post-infection  
299 than those against the spike antigen (16). Nevertheless, this should not impact the sensitivity  
300 analysis in the current results, as nucleocapsid antibodies were detected as the reference.

301

## 302 **Funding**

303 This study was funded by the Special Research Fund of Ghent University  
304 (BOF.COVID.2020.0010.01).

305

306

307

308 **Acknowledgements**

309 The authors wish to thank all residents and their families, staff and management from the  
310 nursing homes that participated in the study.

311

## 312 **References**

- 313 1. Roda WC, Varughese MB, Han D, Li MY. 2020. Why is it difficult to accurately predict  
314 the COVID-19 epidemic? *Infect Dis Model* 5:271-281.
- 315 2. Tuailon E, Bollore K, Pisoni A, Debieesse S, Renault C, Marie S, Groc S, Niels C,  
316 Pansu N, Dupuy AM, Morquin D, Foulongne V, Bourdin A, Le Moing V, Van de Perre  
317 P. 2020. Detection of SARS-CoV-2 antibodies using commercial assays and  
318 seroconversion patterns in hospitalized patients. *J Infect* 81:e39-e45.
- 319 3. Bentov I, Reed MJ. 2015. The effect of aging on the cutaneous microvasculature.  
320 *Microvasc Res* 100:25-31.
- 321 4. Buderer NM. 1996. Statistical methodology: I. Incorporating the prevalence of disease  
322 into the sample size calculation for sensitivity and specificity. *Acad Emerg Med* 3:895-  
323 900.
- 324 5. Brown LD, Cai TT, DasGupta A. 2001. Interval Estimation for a Binomial Proportion.  
325 *Statistical Science* 16:101-133, 33.
- 326 6. Amendola A, Bianchi S, Gori M, Barcellini L, Colzani D, Canuti M, Giacomet V,  
327 Fabiano V, Folgori L, Zuccotti GV, Tanzi E. 2021. Dried Blood Spot as an Alternative  
328 to Plasma/Serum for SARS-CoV-2 IgG Detection, an Opportunity to Be Sized to  
329 Facilitate COVID-19 Surveillance Among Schoolchildren. *Pediatr Infect Dis J* 40:e46-  
330 e47.
- 331 7. Karp DG, Danh K, Espinoza NF, Seftel D, Robinson PV, Tsai CT. 2020. A serological  
332 assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood  
333 spots. *Sci Rep* 10:20188.
- 334 8. McDade TW, McNally EM, D'Aquila R, Mustanski B, Miller A, Vaught LA, Reiser NL,  
335 Bogdanovic E, Zelikovich AS, Demonbreun AR. 2020. Enzyme immunoassay for  
336 SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach  
337 to facilitate community- and population-based screening. *medRxiv*  
338 doi:10.1101/2020.04.28.20081844:2020.04.28.20081844.




- 339 9. Moat SJ, Zelek WM, Carne E, Ponsford MJ, Bramhall K, Jones S, El-Shanawany T,  
340 Wise MP, Thomas A, George C, Fegan C, Steven R, Webb R, Weeks I, Morgan BP,  
341 Jolles S. 2021. Development of a high-throughput SARS-CoV-2 antibody testing  
342 pathway using dried blood spot specimens. *Ann Clin Biochem* 58:123-131.
- 343 10. Morley GL, Taylor S, Jossi S, Perez-Toledo M, Faustini SE, Marcial-Juarez E, Shields  
344 AM, Goodall M, Allen JD, Watanabe Y, Newby ML, Crispin M, Drayson MT,  
345 Cunningham AF, Richter AG, O'Shea MK. 2020. Sensitive Detection of SARS-CoV-2-  
346 Specific Antibodies in Dried Blood Spot Samples. *Emerg Infect Dis* 26:2970-2973.
- 347 11. Mulchandani R, Brown B, Brooks T, Semper A, Machin N, Linley E, Borrow R, Wyllie  
348 D, Investigators E-HS. 2021. Use of dried blood spot samples for SARS-CoV-2  
349 antibody detection using the Roche Elecsys (R) high throughput immunoassay. *J Clin*  
350 *Viro* 136:104739.
- 351 12. Thevis M, Knoop A, Schaefer MS, Dufaux B, Schrader Y, Thomas A, Geyer H. 2020.  
352 Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2  
353 antibody tests? *Drug Test Anal* 12:994-997.
- 354 13. Toh ZQ, Higgins RA, Anderson J, Mazarakis N, Do LAH, Rautenbacher K, Ramos P,  
355 Dohle K, Tosif S, Crawford N, Mulholland K, Licciardi PV. 2021. The use of dried  
356 blood spots for the serological evaluation of SARS-CoV-2 antibodies. *J Public Health*  
357 (Oxf) doi:10.1093/pubmed/fdab011.
- 358 14. Weisser H, Steinhagen K, Hocker R, Borchardt-Loholter V, Anvari O, Kern PM. 2021.  
359 Evaluation of dried blood spots as alternative sampling material for serological  
360 detection of anti-SARS-CoV-2 antibodies using established ELISAs. *Clin Chem Lab*  
361 *Med* 59:979-985.
- 362 15. Boum Y, Fai KN, Nikolay B, Mboringong AB, Bebell LM, Ndifon M, Abbah A, Essaka  
363 R, Eteki L, Luquero F, Langendorf C, Mbarga NF, Essomba RG, Buri BD, Corine TM,  
364 Kameni BT, Mandeng N, Fanne M, Bisseck A-CZ-K, Ndongmo CB, Eyangoh S,  
365 Hamadou A, Ouamba JP, Koku MT, Njouom R, Claire OM, Ezzo L, Epée E, Mballa  
366 GAE. Performance and operational feasibility of antigen and antibody rapid diagnostic


367 tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a  
368 clinical, prospective, diagnostic accuracy study. *The Lancet Infectious Diseases*  
369 doi:10.1016/S1473-3099(21)00132-8.

370 16. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, Farina A, Campos J,  
371 Hacker D, Lau K, Bosch B-J, Gonseth Nussle S, Bochud M, D'Acremont V, Trono D,  
372 Greub G, Pantaleo G. 2021. Changes in SARS-CoV-2 Spike versus Nucleoprotein  
373 Antibody Responses Impact the Estimates of Infections in Population-Based  
374 Seroprevalence Studies. *Journal of virology* 95:e01828-20.


375



**Figure 1. Schematic figure of the collection, screening and analysis of sera and dried blood spots.** CMIA, chemiluminescent microparticle immunoassay; DBS, dried blood spot; EI, EUROIMMUN; ELISA, enzyme-linked immunosorbent assay; WM, Whatman.



**Figure 2. Scatter plot of paired sera and Whatman DBS (left) and Whatman DBS and EUROIMMUN DBS (right) optical density/index values.** Axes represent the log<sub>10</sub> of the optical density and index values. DBS, dried blood spot; FN, false negatives; FP, false positives; OD, optical density. The grey horizontal and vertical lines represent cutoff lines defining positive samples.



**Figure 3. Receiver operating characteristics (ROC) curve for the evaluation of the Whatman DBS ELISA (left) and EUROIMMUN (right) compared to the reference assay.**

The area under the curve is 0.999 for both Whatman and EUROIMMUN DBS (95% CI, 0.999 to 1.000) ( $p < 0.0001$ ).